Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. It is also leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, PJSC Pharmsynthez, and SynBio LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
P/E ratio for Xenetic Biosciences, Inc. (XBIO)
P/E ratio as of 2023: -1.28
According to Xenetic Biosciences, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.28. At the end of 2022 the company had a P/E ratio of -0.63.
P/E ratio history for Xenetic Biosciences, Inc. from 2011 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.28 |
| 2022 | -0.63 |
| 2021 | -2.39 |
| 2020 | -1.20 |
| 2019 | -0.26 |
| 2018 | -2.04 |
| 2017 | -4.63 |
| 2016 | -0.59 |
| 2015 | -0.02 |
| 2014 | -0.01 |
| 2013 | 0.00 |
| 2012 | 0.00 |
| 2011 | 0.00 |